Cough Assist Devices Market Size & Share 2026-2035

Cough Assist Devices Market Size

The global cough assist devices market was estimated at USD 262.3 million in 2025. The market is expected to grow from USD 281.5 million in 2026 to USD 505.1 million in 2035, at a CAGR of 6.7% during the forecast period, according to the latest report published by Global Market Insights Inc. The market is driven by numerous factors, such as rising prevalence of chronic respiratory diseases and neuromuscular disorders, aging global population with weakened respiratory muscles, among other factors.

Cough assist devices are specialized smart medical devices designed to help patients clear mucus and secretions from their airways when they are unable to cough effectively on their own. These devices use a technique called mechanical insufflation-exsufflation, which delivers positive pressure to the lungs followed by rapid negative pressure, simulating a natural cough.

Shift toward home healthcare and long-term care settings is expected to fuel the industry's growth. Philips, Baxter, Smiths Medical, Ventec Life Systems, and Air Liquide Healthcare are among the leading players operating in the market. These players mainly focus on product innovation, geographic expansion, research and development, and collaboration with local or regional healthcare providers, among other factors.

The market has increased from USD 205.1 million in 2022 and reached USD 242.8 million in 2024, with a historic growth rate of 8.8%. The rising prevalence of chronic respiratory diseases and neuromuscular disorders is a key driver of the cough assist devices industry, as these conditions impair the natural ability to clear airway secretions and necessitate assisted respiratory support. According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally, accounting for 3.4 million deaths in 2023, representing approximately 6% of all global deaths. In addition, based on NIH 2023 data, neuromuscular diseases affect nearly 15 million people worldwide, further highlighting the growing patient population requiring respiratory assistance. This increasing disease burden is significantly driving demand for cough assist devices, as they play a critical role in improving airway clearance, reducing complications, and enhancing patient outcomes in both clinical and homecare settings.

The rapidly aging global population with weakened respiratory muscles is a significant driver of the cough assist devices market, as older individuals are more prone to respiratory complications and reduced airway clearance capacity. According to the World Health Organization (WHO), by 2030, 1 in 6 people globally will be aged 60 years or older, with the elderly population increasing from 1 billion in 2020 to 1.4 billion. Furthermore, by 2050, this population is expected to double to 2.1 billion, while the number of individuals aged 80 years and above is projected to triple to 426 million. This sharp rise in the aging population is increasing the incidence of respiratory muscle weakness, chronic lung conditions, and reduced cough efficiency, thereby driving the demand for cough assist devices. These devices play a critical role in improving airway clearance, preventing infections, and enhancing overall respiratory function among elderly patients, supporting sustained market growth.

Cough Assist Devices Market Trends

The continuous technological advancements in portable, automated, and connected cough assist devices play a critical role in driving market growth by improving therapy efficiency, enhancing patient compliance, and enabling better respiratory care management.

• Advanced cough assist devices are increasingly being developed with features such as automated insufflation-exsufflation cycles, adjustable pressure settings, and compact, portable designs, which improve ease of use and allow personalized therapy. These devices enable effective airway clearance by simulating natural cough mechanisms while minimizing patient discomfort. The shift toward lightweight and portable systems supports increased use in homecare settings, improving accessibility and continuity of treatment.
• The integration of digital interfaces, programmable therapy modes, and real-time performance monitoring enables better treatment adherence and allows healthcare providers to optimize therapy remotely. Additionally, connected features support data tracking and telehealth integration, facilitating improved patient management and follow-up care, particularly for individuals with chronic neuromuscular and respiratory conditions.
• For instance, Philips Respironics’ CoughAssist E70 offers customizable therapy settings and advanced monitoring capabilities, enabling effective secretion clearance in both hospital and home environments. Similarly, Breas Medical’s Vivo 45 LS ventilator system with cough assist compatibility supports integrated respiratory care with automated therapy features, enhancing patient comfort and treatment efficiency.
• Collectively, these technological innovations highlight a strong industry focus on portability, automation, and digital integration, thereby reinforcing advancements in cough assist devices as a key factor supporting the sustained growth of the cough assist devices industry.

Cough Assist Devices Market Analysis

Based on product type, the cough assist devices market is segmented into automatic cough assist device and manual cough assist device. The automatic cough assist device segment accounted for a dominant market share of 72.3% in 2025, driven by their advanced programmability, and easier use, along with better efficiency in secretion clearing compared to manual alternatives. The segment is expected to exceed USD 370.1 million by 2035, growing at a CAGR of 6.9% during the forecast period.

• The automatic cough assist device segment grows strongly since the demand for advanced non-intrusive airway clearance solutions rises. These solutions offer much higher efficiency as well as comfort to the patients in comparison with the manual alternatives. These devices are equipped with programmable pressure settings, customizable cycles, and digital interfaces, enabling clinicians to deliver personalized therapy for patients with varying severity of respiratory or neuromuscular conditions.

• Their ease of use reduces dependency on caregivers and minimizes the risk of inconsistent therapy, making them highly suitable for both hospital and homecare settings. Growing awareness among healthcare providers about the clinical benefits of automated insufflation-exsufflation therapy, coupled with supportive reimbursement policies in developed countries, further drives adoption.
• Additionally, technological innovations such as portable and compact models with battery backup have enhanced patient mobility and broadened usage in long-term care and home environments.
• The manual cough assist device segment is projected to expand at a 6.3% CAGR to reach USD 135.1 million by 2035, driven by its affordability, portability, and increasing adoption in low-resource healthcare settings where cost is a critical factor. Manual devices are simple to operate, lightweight, and require no power source, making them especially valuable in rural and developing regions with limited access to advanced medical technologies. Their cost-effectiveness also makes them a preferred option for patients and providers in markets with limited or inconsistent reimbursement coverage.

Based on the choice of delivery, the cough assist devices market is segmented into mouth piece, face mask, and adapter. The mouth piece segment accounted for the highest market share of 45.5% in 2025 due to its convenience, patient comfort, and suitability as respiratory therapies for use in hospitals and homes.

• The mouthpiece segment represented the dominating component category in the cough assist devices industry, driven by its widespread use, ease of application, and effectiveness in delivering controlled airway clearance therapy. Mouthpieces are commonly preferred in adult and cooperative patient populations as they enable direct delivery of insufflation and exsufflation airflow with minimal leakage, ensuring efficient secretion clearance.
• Their non-invasive nature and reusability make them suitable for both clinical and homecare settings, where patient compliance and convenience are critical. Additionally, the ability to provide precise pressure delivery and better patient control during therapy further reinforces the dominance of the mouthpiece segment in the market.
• Innovations focusing on hygienic materials, ease of cleaning, and compatibility with portable devices are making them ideal for long-term respiratory therapy. These improvements, combined with their cost-effectiveness and suitability for self-administered therapy, continue to strengthen the leadership position of the mouthpiece segment in the cough assist devices industry.
• The face mask segment is projected to expand at a 7.2% CAGR to reach USD 186.2 million by 2035. The face mask segment is witnessing steady growth, supported by its suitability for pediatric patients, elderly individuals, and non-cooperative users. Face masks provide a secure seal and enable effective therapy delivery without requiring active patient participation, making them highly relevant in cases where mouthpiece use is not feasible. Increasing demand from hospitals and critical care settings is further driving adoption, particularly for patients requiring assisted ventilation and airway clearance.
• The adapter segment is projected to expand at 6.3% CAGR to reach USD 93.7 million by 2035. Adapters are used to connect cough assist devices with tracheostomy tubes, ventilation circuits, and other interfaces, ensuring seamless therapy delivery. The growing use of integrated respiratory care systems and the need for flexible connectivity solutions are supporting demand for adapters, particularly in hospital and intensive care environments.

• Increasing hospital admissions for conditions like COPD exacerbations, cystic fibrosis, and pneumonia create consistent demand for non-invasive airway clearance therapies. Hospitals prefer advanced cough assist devices for their programmable features, reliability, and ability to deliver high therapeutic efficiency under clinical supervision. The presence of trained healthcare professionals ensures optimal usage, improved patient outcomes, and adherence to treatment protocols.
• Additionally, government support, insurance reimbursement policies, and hospital budgets allocated for modern respiratory care equipment encourage adoption. Hospitals also serve as centers for clinical research and pilot programs, enabling rapid integration of next-generation devices. The combination of patient volume, clinical expertise, and institutional support drives the segment’s dominance, making it a critical growth engine within the cough assist devices industry.
• The homecare settings segment is projected to expand at 7% CAGR to reach USD 196.1 million by 2035. Patients with chronic respiratory disorders and neuromuscular conditions increasingly prefer receiving therapy at home to avoid frequent hospital visits and reduce infection risk. Portable and user-friendly cough assist devices allow caregivers or patients themselves to perform effective airway clearance, promoting adherence and long-term health outcomes.
• Advances in telehealth and remote monitoring technologies further enhance the appeal of homecare solutions by enabling clinicians to track therapy progress and adjust protocols remotely. Aging populations, particularly in developed countries, are contributing to the increased demand for home-based respiratory support, while supportive reimbursement policies and insurance coverage in key markets further facilitate adoption.
• The other end users segment is projected to expand at a 6% CAGR to reach USD 101.2 million by 2035. The other end users segment, which includes rehabilitation centers, long-term care facilities, and outpatient clinics, is growing steadily due to the increasing need for continuous respiratory support outside traditional hospital environments. These settings cater to patients requiring ongoing therapy and monitoring, particularly those transitioning from hospital to homecare.

 North America Cough Assist Devices Market

The North America cough assist devices industry accounted for a majority share of 36.5% in 2025 and is anticipated to show notable growth over the forecast period.

• The U.S. cough assist devices industry was valued at USD 71.9 million and USD 77.7 million in 2022 and 2023, respectively. The market size reached USD 89.6 million in 2025, growing from USD 83.6 million in 2024, and is anticipated to grow at a CAGR of 5.7% from 2026 to 2035.
• The North America cough assist devices industry is significantly driven by the rising prevalence of chronic respiratory diseases and neuromuscular conditions, which are increasing the need for effective airway clearance solutions. According to the U.S. Department of Health and Human Services, approximately 25 million people in the U.S. are living with asthma, while over 16 million individuals are affected by chronic obstructive pulmonary disease (COPD). These conditions are associated with impaired mucus clearance and increased risk of respiratory complications, thereby creating a strong demand for cough assist devices in both hospital and homecare settings.
• This growing disease burden is further reinforced by the increasing need for preventive respiratory care and effective disease management strategies. Patients suffering from asthma, COPD, and neuromuscular disorders often require assisted coughing mechanisms to clear secretions and reduce the risk of infections or hospitalizations. As healthcare providers focus on improving patient outcomes and reducing acute exacerbations, the adoption of advanced cough assist devices is increasing across North America, thereby supporting sustained market growth.

Europe Cough Assist Devices Market

Europe accounted for a significant share of the cough assist devices industry and was valued at USD 74.8 million in 2025.

• The Europe cough assist devices industry is experiencing steady growth, driven by the rising prevalence of chronic respiratory diseases and neuromuscular disorders across the region. According to the World Health Organization (WHO), chronic respiratory diseases (CRDs) are among the most common noncommunicable diseases and are closely linked to major causes of mortality such as cardiovascular disease and cancer.
• CRDs are the sixth leading cause of death in the WHO European Region, accounting for nearly 400,000 deaths annually, with around 80% of these deaths attributed to chronic obstructive pulmonary disease (COPD). Furthermore, approximately 81.7 million people are living with CRDs in the region, with 6.8 million new cases reported in 2021, highlighting a significant and growing patient population that requires effective airway clearance therapies.
• In addition, the shift toward home healthcare and long-term care settings is further accelerating the adoption of cough assist devices across Europe. As healthcare systems emphasize reducing hospital burden and improving patient quality of life, there is increasing demand for portable and user-friendly devices that can be used outside clinical environments. Patients with chronic respiratory and neuromuscular conditions require continuous therapy, and home-based care models provide a cost-effective and convenient solution. The integration of cough assist devices into long-term care and community healthcare settings is enabling better disease management, improving treatment adherence, and supporting sustained market growth across the European region.

Asia Pacific Cough Assist Devices Market

The Asia Pacific cough assist devices industry accounted for a substantial share of the market and was valued at USD 65.6 million in 2025.

• The Asia Pacific cough assist devices industry is witnessing strong growth, driven by the rapidly aging population, which is increasingly vulnerable to respiratory muscle weakness and reduced airway clearance capacity. According to UNFPA Asia and the Pacific, by 2050, one in four people in the region will be over 60 years old, and the elderly population is expected to triple between 2010 and 2050, reaching close to 1.3 billion. This significant demographic shift is leading to a sharp rise in age-related respiratory conditions, reduced lung function, and weakened cough mechanisms, thereby increasing the need for assisted airway clearance solutions.
• As a result, the demand for cough assist devices is rising across both hospital and homecare settings, particularly for elderly patients requiring long-term respiratory support. These devices play a critical role in improving mucus clearance, preventing respiratory infections, and enhancing overall quality of life among aging populations. The growing burden of age-related respiratory disorders, combined with increasing awareness and improving access to respiratory care, is expected to drive sustained adoption of cough assist devices across the Asia Pacific region.

Latin America Cough Assist Devices Market

The Latin America cough assist devices industry is anticipated to exhibit remarkable growth during the analysis period.

• The Latin America cough assist devices industry is growing steadily, supported by the increasing prevalence of chronic respiratory diseases such as COPD, asthma, and cystic fibrosis, along with neuromuscular disorders that impair airway clearance. The region’s large and aging population is contributing to a higher incidence of respiratory complications, prompting healthcare providers across hospitals, homecare settings, and long-term care facilities to adopt advanced airway clearance technologies.
• In addition, the expansion of healthcare infrastructure and supportive government initiatives for chronic disease management are strengthening market growth across the region. Improved access to public and private insurance schemes is enabling wider adoption of respiratory care devices. At the same time, technological advancements such as portable, battery-operated, and telehealth-enabled cough assist devices are supporting the shift toward home-based therapy, reducing hospital dependency, and improving patient outcomes.
• Furthermore, increasing awareness initiatives among patients and caregivers regarding early intervention in respiratory care are driving adoption across both urban and semi-urban areas. Enhanced focus on preventive care and disease management is encouraging timely use of cough assist devices, thereby supporting consistent market expansion across Latin America.

Middle East and Africa Cough Assist Devices Market

The Middle East and Africa cough assist devices industry is expected to experience substantial growth over the analysis timeframe.

• The Middle East and Africa (MEA) cough assist devices industry is witnessing gradual growth, driven by the increasing prevalence of chronic respiratory diseases such as COPD, asthma, and bronchiectasis, along with a rising incidence of neuromuscular disorders that impair airway clearance. The growing elderly population, combined with a high rate of smoking-related respiratory complications in several countries, is contributing to a higher burden of respiratory conditions, thereby increasing the need for effective airway clearance solutions across hospitals and homecare settings.
• Furthermore, the expansion of healthcare infrastructure and adoption of advanced medical technologies are supporting market development across the region. Increasing hospital capacities, along with rising investments in modern healthcare systems and long-term care facilities, are improving access to respiratory care devices. Government-led initiatives, particularly under programs such as Saudi Arabia’s Vision 2030, are focused on healthcare modernization and improved chronic disease management, enhancing the availability and affordability of advanced cough assist devices.
• In addition, technological advancements such as portable, battery-operated, and telehealth-enabled cough assist devices are accelerating adoption across MEA. These innovations enable effective home-based therapy, improve patient compliance, and reduce the need for frequent hospital visits. The growing emphasis on patient-centric care and improved treatment outcomes is expected to support the continued expansion of the cough assist devices industry across the region.

Cough Assist Devices Market Share

• Leading companies like Philips, Baxter, Air Liquide Healthcare, Smiths Medical (ICU Medical), and Ventec Life Systems together hold between 55% of the market share in the cough assist devices industry.
• This indicates a competitive landscape where a handful of established multinational companies dominate, while smaller regional and niche players capture the remaining market. The dominance of these top players is driven by their strong brand presence, extensive distribution networks, robust research and development capabilities, and diversified product portfolios that cater to both hospital and homecare segments. Their ability to offer advanced, programmable, and patient-friendly devices with integration into telehealth and digital monitoring platforms provides a competitive advantage, ensuring widespread adoption and customer loyalty.
• Despite the strong presence of leading companies, the market is fragmented among regional manufacturers, emerging innovators, and specialized respiratory device providers. These smaller players often focus on niche markets, cost-effective solutions, or portable devices suited for homecare, thereby gradually expanding their footprint in developing regions and underserved markets. The presence of these competitors ensures continuous innovation, price competition, and the development of patient-centric technologies, which collectively drive overall market growth.

Cough Assist Devices Market Companies

A few of the prominent players operating in the cough assist devices industry include:

• ABM Respiratory Care
• Air Liquide Healthcare
• Baxter
• Breas Medical
• Dima Italia
• PARI
• Philips
• Physio Assist (Simeox)
• Seoil Pacific
• ICU Medical
• Ventec Life Systems
• Vitalograph
• West Care Medical

• Philips

Philips leads the cough assist devices industry with a share of 18.5% in 2024. Philips’ USP lies in its advanced CoughAssist E70 device, combining programmable insufflation-exsufflation therapy with reliability, ease of use, and global hospital-homecare reach. Its strong research and development capabilities, integration with telehealth platforms, and comprehensive respiratory care portfolio ensure superior patient outcomes, widespread adoption, and leadership in the cough assist devices industry.

• Baxter

Baxter’s USP is its established expertise in respiratory care, offering clinically validated, high-performance cough assist devices for hospitals and home care. The company leverages strong distribution networks, patient-centric design, and continuous innovation to enhance therapeutic efficacy, safety, and accessibility, positioning it as a trusted provider of airway clearance solutions globally.

• Air Liquide Healthcare

Air Liquide Healthcare’s USP centers on its integrated respiratory care solutions, strong European presence, and homecare-focused device offerings. With expertise in patient support, robust service networks, and technologically advanced cough assist systems, the company provides personalized, reliable, and effective airway clearance therapy, strengthening adoption and market position worldwide.

Cough Assist Devices Industry News:

• In September 2024, Baxter International launched its next-generation airway clearance system, the Vest Advanced Pulmonary Experience (APX) System, at the North American Cystic Fibrosis Conference, enhancing therapy options for patients with chronic respiratory conditions. This launch strengthened Baxter’s respiratory care portfolio, improved its technological positioning, and helped the company expand its presence in advanced airway clearance solutions.
• In December 2024, Inogen Inc. received U.S. FDA 510(k) clearance for the SIMEOX 200 airway clearance device, designed to support effective treatment of patients with chronic respiratory diseases across the U.S. This approval enabled Inogen to broaden its product offerings, enhance its regulatory standing, and helped the company expand its reach in the airway clearance and respiratory care market.

The cough assist devices market research report includes an in-depth coverage of the industry with estimates and forecasts in terms of revenue in (USD Million) from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Automatic cough assist device

• Manual cough assist device

Market, By Choice of Delivery

• Mouth piece

• Face mask
• Adapter

Market, By End Use

• Hospitals

• Home care settings
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE